Literature DB >> 2372762

Long-term cardiac sequelae after treatment of malignant tumors with radiotherapy or cytostatics in childhood.

L Mäkinen1, A Mäkipernaa, J Rautonen, M Heino, S Pyrhönen, L A Laitinen, M A Siimes.   

Abstract

A series of 41 individuals were restudied after childhood cancer with a median follow-up time of 17 years after chest irradiation or treatment with cyclophosphamide or Adriamycin (doxorubicin). Radiotherapy of the chest had been used in 21 patients, and in 13 of these irradiation was also directed at the heart. Thirty-five patients received cyclophosphamide and five received Adriamycin therapy. All patients were investigated by a pediatric cardiologist. Investigations included an electrocardiogram (ECG), a chest radiographic film, an echocardiogram, an exercise test, and a 24-hour ECG. Altogether 20 patients (49%) showed some abnormality in cardiac tests. Each additional year of follow-up was associated with a 1.3-fold (95% confidence limits, 1.04-1.66; P less than 0.05) increase in the risk for pathologic cardiac findings. The risk for an abnormal cardiac test result in the 13 patients who had received cardiac irradiation was 12.8-fold (95% confidence limits, 1.8-90.8; P less than 0.02) that of the other patients. However, abnormalities in cardiac function were mild.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372762     DOI: 10.1002/1097-0142(19900501)65:9<1913::aid-cncr2820650907>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Late cardiac effects after treatment for childhood Hodgkin's disease with chemotherapy and low-dose radiotherapy.

Authors:  I Ilhan; F Sarialioglu; N Ozbarlas; M Büyükpamukçu; C Akyüz; T Kutluk
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

Review 2.  Exercise and Childhood Cancer-A Historical Review.

Authors:  Javier S Morales; Pedro L Valenzuela; Daniel Velázquez-Díaz; Adrián Castillo-García; David Jiménez-Pavón; Alejandro Lucia; Carmen Fiuza-Luces
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.